Compare Agilent Technologies Inc (A) vs CSX Corporation (CSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs CSX Corporation — how do they compare? Agilent Technologies Inc trades at $128.42 (market cap $37.04B), while CSX Corporation trades at $48.13 (market cap $90.14B). The key difference: CSX Corporation is far larger — about 2.4× Agilent Technologies Inc's market cap, and CSX Corporation pays the higher dividend (1.15%). Which is the better fit depends on your goals.
| A | CSX | |
|---|---|---|
Market Cap | $37.04B | $90.14B |
Sector | Health | Industrials |
52-Week High | $157.20 | $48.89 |
52-Week Low | $110.24 | $32.05 |
Enterprise Value | $38.59B | $108.37B |
Dividend Yield | 0.78% | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
CSX trades at $48.51, down 0.78% on the day, with a bullish technical outlook from moving averages but neutral oscillators. The company reported a net income margin of 21.55% for 2025, though revenue has declined from $14.9B in 2022 to $14.1B in 2025. Analyst consensus is a Buy with a $46.83 price target, and the stock has seen positive news coverage highlighting operational improvements and a recent dividend declaration.
The outlook for CSX is cautiously optimistic, supported by strong profitability metrics and analyst upgrades, but tempered by declining revenue trends and high valuation multiples. Key risks include freight demand volatility and competitive pressures, while institutional sentiment remains positive with a majority of analysts recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
